RecruitingNot ApplicableNCT05937620

Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer

Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and Indocyanine Green (ICG) in Patients With Epithelial Ovarian Cancer in Early Stages: Pilot Study

Sponsor

Fundacion Clinic per a la Recerca Biomédica

Enrollment

62 participants

Start Date

Sep 1, 2023

Study Type

INTERVENTIONAL

Conditions

Ovarian Epithelial Cancer

Summary

Study to evaluate the diagnostic precision of ICG and 99mTc nanocolloid albumin in sentinel lymph node detection in early ovarian epithelial cancer.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a technique to identify and remove sentinel lymph nodes (the first nodes cancer may spread to) in women with early-stage ovarian cancer, using a combination of a radioactive tracer and a fluorescent dye called ICG. **You may be eligible if...** - You have an ovarian mass that looks suspicious for cancer and will have an intraoperative biopsy - Or you have already been diagnosed with early-stage epithelial ovarian cancer and are scheduled for full surgical staging - You do not have spread of cancer outside the pelvis at the time of diagnosis **You may NOT be eligible if...** - Your cancer has already spread widely in the abdomen - You have conditions that would make the procedure unsafe - You do not consent to the procedure Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.